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The expression of Smad interacting protein-1 (SIP1; ZEB2) and the de novo expression of vimentin are 
frequently involved in epithelial-to-mesenchynial transitions (EMTs) under both normal and pathological 
conditions. In the present study, we investigated the potential role of SIP1 in the regulation of vimentin during 
the EMT associated with breast tumor cell migration and invasion. Examining several breast tumor cell Unes 
displaying various degrees of invasiveness, we found SIP1 and vimentin expression only in invasive cell Unes. 
Also, using a model of cell migration with human mammary MCF10A cells, we showed that SIP1 is induced 
specifically in vimentin-positive migratory cells. Furthermore, transfection of SIP1 cDNA in MCF10A cells 
increased their vimentin expression both at the mRNA and protein levels and enhanced their migratory abilities 
in Boyden Chamber assays. Inversely, inhibition of SIP1 expression by RNAi strategies in BT-549 cells and 
MCF10A cells decreased vimentin expression. We also showed that SIP1 transfection did not activate the TOP-
FLASH reporter system, suggesting that the β-catenin/ TCF pathway is not impUcated in the regulation of 
vimentin by SIP1. Our results therefore impUcate SIP1 in the regulation of vimentin observed in the EMT 
associated with breast tumor cell migration, a pathway that may contribute to the metastatic progression of breast 
cancer. 
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Introduction 
During their metastatic conversion, epithelial cells acquire the ability to invade the surrounding tissue and   
disseminate into secondary organs. There is mounting evidence that the acquisition of migratory and invasive 
properties by epithelial cells is associated with the gain of mesenchymal characteristics and the loss of epithelial 
features, a phenomenon referred to as epithelial-to-mesenchymal transition (EMT) (Savagner, 2001; Thiery, 
2002; Gotzmann et al., 2004; Gilles et al., 2004). 
A growing number of zinc-finger transcription factors has now been implicated in the regulation of EMT 
phenomena. Among them is SIP1 (Smad Interacting Protein-1) or ZEB2, a large zinc-finger protein that, 
together with δEF1, belongs to a small family of transcriptional repressors. It has originally been identified as a 
factor binding the Smad proteins, implicated in the signaling by TGF-β (Verschueren et al., 1999). The 
δEF1/ZEB family comprises two vertebrate prototypes (δEF1/ZEB1 and SIP1/ZEB2) characterized by two zinc-
finger clusters separated by a homeodomain. The N-terminal and C-terminal zinc-finger clusters are made of 
four and three zinc fingers, respectively. Each zinc-finger cluster recognizes a CACCT motif on the DNA but the 
full-length SIP1 molecule has been shown to bind a bipartite element composed of one 5'-CACCT and one              
5'-CACCTG sequence (Remacle et al., 1999; Verschueren et al., 1999). A mechanism by which SIP1 might 
contribute to EMT processes is through its ability to downregulate E-cadherin. Indeed, SIP1 has been shown to 
bind the E-cadherin promoter and to downregulate the expression of this cell adhesion protein (Comijn et al., 
2001; van Grunsven et al., 2003). E-cadherin is a transmembrane glycoprotein that mediates homotypic cell-cell 
contacts between epithelial cells and, thereby, largely contributes to the cohesive architecture of normal 
epithelia. The cytoplasmic part of E-cadherin is associated with the actin cytoskeleton via its cytoplasmic 
binding partners, the catenins (α-, β- and γ- catenin). Under particular conditions, when β-catenin is not 
sequestered in the junctional E-cadherin complexes, it can translocate in the nucleus where it acts as a 
transcriptional coactivator through its binding with the members of the TCF/LEF-1 (T-cell factor/lymphoid 
enhancer factor) transcription factor family (Bienz, 2005). Downregulation of E-cadherin expression and 
reorganization of E-cadherin-based adhesion junctions are considered hallmarks of EMT processes and have 
largely been implicated in EMT associated with the acquisition of a migratory/invasive phenotype by epithelial 
tumor cells (Comijn et al., 2001; Van Aken et al., 2001; Peinado et al., 2004). 
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Besides the disorganization of E-cadherin-based junctional complexes, the de novo expression of vimentin is 
also frequently associated with EMT processes and with the metastatic conversion of epithelial cells. Vimentin is 
a type-Ill intermediate filament normally expressed in cells of mesenchymal origin (Steinert and Roop, 1988). 
However, numerous data have now demonstrated that vimentin can also be expressed in epithelial cells when 
they become involved in physiological or pathological processes requiring epithelial cell migration. Vimentin 
has indeed been described in migratory epithelial cells involved in embryonic and organogenesis processes, in 
placentation, wound healing and tumor invasion (Ramaekers et al., 1983; Guarino, 1995; Gilles and Thompson, 
1996; Gilles et al., 1999, 2003). Also, vimentin-specific antisense cDNA or oligonucleotide transfection in 
vimentin-expressing cell lines was shown to reduce their in vitro invasiveness or migration, strongly 
emphasizing a functional contribution of vimentin to epithelial cell invasion/migration (Hendrix et al., 1997; 
Gilles et al., 1999; Singh et al., 2003). Accordingly, impaired wound healing has been observed in vimentin 
knockout mice (Eckes et al., 1998, 2000). Furthermore, a direct or indirect interaction of vimentin with 
microfilaments and microtubules and more particularly with molecules such as plectin or integrins has been 
described (Svitkina et al., 1996; Maniotis et al., 1997; Homan et al., 1998; Goldman et al., 1999; Wu et al., 
1999; Gonzales et al., 2001; Tsuruta and Jones, 2003; Helfand et al., 2004; Kreis et al., 2005). A role of 
vimentin in the mechanical transduction of signals from the cell surface to the nucleus and in the overall 
reorganization of the cytoskeleton associated with cell motility and migration has therefore been suggested 
(Hendrix et al., 1996; Gilles et al., 1999; Eckes et al., 2000; Helfand et al., 2004). 
Because both SIP1 and vimentin expression are clearly associated with EMT events, we thus examined in the 
present study the implication of SIP1 in the induction of vimentin expression associated with epithelial cell 
migration and invasion. We also explored the potential role of the β-catenin/TCF pathway in this regulation. 
Results 
Vimentin expression correlates with SIP1 expression in migratory /invasive breast cell lines  
In order to examine the relationship between SIP1 and vimentin, we first analysed their expression in two non-
invasive (MCF-7, T47D) and three invasive (MDA-231, BT549, Hs578T) epithelial breast cancer cell lines. The 
invasive phenotype of these breast cancer cells, as assessed by modified Boyden chamber assays, as well as their 
vimentin and E-cadherin expression status have been characterized in previous studies which established a clear 
association between high invasive properties and EMT traits such as vimentin expression and lack of E-cadherin 
expression (Thompson et al., 1992; Sommers et al., 1994; Nawrocki et al., 2001). Examining SIP1 in this set of 
breast cell lines, we observed that invasive breast cancer cell lines showed both SIP1 and vimentin mRNA 
expression in contrast to non-invasive cells (Figure 1). SIP1 and vimentin mRNA expression was also analysed 
in primary airway human fibroblasts versus primary human differentiated epithelial cells. Cells isolated from 
airway tissues were used because of the possibility to obtain a clear epithelial differentiation, characterized by 
the presence of ciliated cells, when cultivated in appropriate culture conditions. In support of the results obtained 
with the tumor cell lines suggesting that the invasive cell lines have gained mesenchymal characteristics, a weak 
expression of vimentin and no detectable expression of SIP-1 was found in differentiated lung epithelial cells 
whereas both mRNA were strongly co-expressed in fibroblasts (Figure 1). 
 
Figure 1 Expression of SIP1 correlates with vimentin expression in human breast cancer cell lines. RT-PCR 
analyses of vimentin and SIP1 were performed on five human tumor cell lines (T47D, MCF-7, MDA-231, BT549 
and Hs578T) as well as in primary fibroblasts (Fibro.) and differentiated primary epithelial (Epith.) cells 
isolated from human airway tissues. 28S rRNA analysis is shown as control. 
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Figure 2 Expression of SIP1 correlates with vimentin expression in migratory MCF10A cells. (a) Single or 
double visualization (merge) of vimentin (in red) and EGFP expression driven by the vimentin promoter (in 
green) in VP-EGFP MCF10A cells plated in the migration assay. DAPI staining is in blue. The white line 
schematically represents the limit between the vimentin-positive and the vimentin-negative cell population. Bar 
= 80µm. (b, c) RT-PCR analyses for SIP1 and vimentin were performed on migratory (mig) and stationary (stat) 
subpopulations sorted by FACS for GFP expression of two clones (#11 and #12) of VP-EGFP MCF10A plated 
in the migration assay in complete growth medium (FCS + EGF) (b) or in FCS-free, EGF-containing growth 
medium (c). 28S rRNA analysis is shown as control. Quantification of RT-PCR analyses of vimentin and SIP1 
normalized for the 28S rRNA values in three independent migration and FACS sorting experiments, as described 




Next, we studied SIP1 expression in relation to vimentin expression in a migration assay that we had previously 
used to demonstrate the transient expression of vimentin during epithelial cell migration (Gilles et al., 1999, 
2003). Briefly, in this migration assay, MCF10A human breast cells are plated at high density in a glass ring and 
migrate as an outgrowth after the removal of the ring. In this assay, vimentin expression has been shown to vary 
in relationship with the migratory status of the cells. Using video microscopy, we indeed previously 
demonstrated that the subpopulation of cells at the periphery of the outgrowth is involved in an orientated 
migration and undergoes an EMT process characterized by the de novo expression of vimentin and a 
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relocalization of E-cadherin and β-catenin (Gilles et al., 1999, 2003). In contrast, the stationary cells in the area 
initially delimited by the ring do not express vimentin and display a typical honeycomb pattern of E-cadherin 
and β-catenin staining. In the present study, we used two clones (#11 and #12) of MCF10A cells stably 
transfected with a plasmid containing the vimentin promoter controlling the expression of the enhanced green 
fluorescent protein (EGFP) gene (VP-EGFP MCF10A cells as previously described in Gilles et al., 1999). The 
VP-EGFP MCF10A cells were plated in the migration assays and sorted by FACS to physically separate the 
GFP-positive and the GFP-negative populations (Figure 2a). RT-PCR performed on these two separated cell 
populations clearly showed co-expression of SIP1 and vimentin mRNA in the migratory subpopulation (Figure 
2b). 
The effect of EGF on vimentin and SIP1 co-expression was also investigated in this assay. We indeed previously 
showed that EGF, which is present in the growth medium of the MCF10A cells, induces vimentin expression in 
migratory MCF10A cells even in the absence of serum. Similar to our observations in the presence of complete 
growth medium (containing FCS and EGF) (Figure 2b), a strong co-expression of vimentin and SIP1 mRNA was 
also found in the migratory subpopulation of the two clones of VP-EGFP MCF10A plated in EGF-containing, 
serum-free medium (Figure 2c). 
Smad interacting protein-1 regulates vimentin expression 
 Because of the correlation between vimentin and SIP1 expression in both the breast cancer cell line panel and 
the MCF10A migration assay, we examined whether SIP1 could regulate vimentin expression. We first observed 
that transient transfection of SIP1 cDNA for 24, 48 or 72 h clearly induced vimentin expression both at the 
mRNA (Figure 3a) and at the protein (Figure 3b) levels. This correlated with increased migratory properties in 
the Boyden chamber assay (Figure 3c). 
 
Inversely, we investigated the effect of an inhibition of SIP1 on vimentin expression using RNAi strategies both 
on MCF10A cells and on vimentin-positive BT549 cells. Because an efficient diminution of SIP1 could not be 
achieved in MCF10A cells by transient transfection of SIP1 siRNA, these cells were transduced with two 
lentiviral constructs expressing two different SIP1 short hairpin RNA (shRNA) sequences which efficiently 
diminished SIP1 mRNA levels (Figure 4a). The SIP1 shRNA construct transduction also diminished vimentin 
expression both at the mRNA (60% decrease compared to control transduced cells) and at the protein level 
(Figure 4a and b). This was associated with a diminution of migratory properties in the Boyden chamber assay 
(Figure 4c). Strengthening these data obtained with MCF10A cells, we also showed that transient transfections 
of two species of SIP1 siRNA in vimentin-positive BT549 cells significantly decreased vimentin mRNA levels 
(34 and 28% decrease for siRNA 1 and 2, respectively) (Figure 5a). A decrease of vimentin protein expression 
was also observed (Figure 5b). 
Because vimentin has been shown to be a target of the β-catenin/TCF pathway (Gilles et al., 2003) and because 
SIP1 has been described as a potent transcriptional repressor of E-cadherin (Comijn et al., 2001; van Grunsven et 
al., 2003), we examined whether the regulation of vimentin by SIP1 involved the β-catenin/ TCF pathway. A 
downregulation of E-cadherin may indeed result in increased availability of β-catenin in the nucleus. We thus 
first confirmed that SIP1 and E-cadherin expression were inversely correlated in the breast tumor cell lines 
(Figure 6a). This was also seen in the MCF10A migration assay (Figure 6b). Furthermore, transfection of SIP1 
cDNA in MCF10A cells decreased the level of E-cadherin mRNA in these cells (Figure 6c). In order to analyse 
the implication of the β-catenin/TCF pathway in SIP1-induced vimentin expression, we next examined the 
ability of SIP 1 to transactivate a luciferase reporter plasmid containing wild-type (TOP-FLASH) or mutated 
(FOP-FLASH) β-catenin/TCF-binding sites as regulatory elements. Although SIP1 cDNA transfection clearly   
activated   the   vimentin   promoter   reporter construct (Figure 7a), it failed to activate the TOP-FLASH reporter 
system (Figure 7b). This suggests that SIP1 does not activate the β-catenin/TCF pathway. Accordingly, we did 
not observe any increase of β-catenin in the nuclear fraction (nor in the membranous or cytosolic fractions) of 
cells transfected with SIPl cDNA though the presence of the myc-tagged SIPl was detected (Figure 7c). Since it 
has been suggested that the NH2-unphosphorylated form of β-catenin is mainly implicated in the transcriptional 
activity of β-catenin (Staal et al., 2002), we also examined this particular form of β-catenin. Using a specific 
antibody against the unphosphorylated β-catenin, we still did not observe any increase of this particular form in 
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Figure 3 SIP1 transfection regulates vimentin expression, (a) RT-PCR analyses of vimentin and SIP1 expression 
in MCF10A cells transiently transfected with SIP1 cDNA for 24, 48 or 72h. Quantification of RT-PCR analyses 
of vimentin, normalized for the 28S rRNA values, in three independent transfection experiments is shown. Data 
are expressed as fold induction in SIP1 transfectants relative to the backbone vector transfectants (P<0.05). (b) 
Western blotting analyses of vimentin expression in MCF10A cells transiently transfected with SIP1 cDNA for 
24, 48 or 72h. Actin detection is shown as a control. A representative experiment is shown out of three 
independent experiments performed, (c) Boyden chamber analyses of the migratory abilities of MCF10A 
transfected for 48 h with the SIP1 cDNA (SIP1) or the backbone vector (Cont). Data are expressed as fold 
induction for SIP1 transfectants relative to the backbone vector transfectants (P<0.05). 
 
 
Published in: Oncogene (2006), vol. 25, iss. 36, pp. 4975-4985. 
Status : Postprint (Author’s version) 
 
Figure 4 SIP1 shRNA decreased vimentin expression and migratory abilities of MCF10A cells. MCF10A cells 
were transduced with lentiviral constructs expressing two different sequences of SIP1 shRNA (SIP1sh1, 
SIP1sh2) or with a control vector (Cont). (a) RT-PCR analyses of vimentin and SIPl in the SIPl shRNA-
expressing cells compared to the control cells. Quantification of RT-PCR analyses of vimentin normalized for 
the 28S rRNA values in three independent transfection experiments is shown. Data are expressed as fold 
induction in shRNA-expressing cells relative to the controls (P<0.01). (b) Western blot analyses of vimentin 
expression in SIPl shRNA-expressing cells. Actin was used as a control. A representative experiment is shown 
out of three independent experiments performed. (c) Analyses of the migratory abilities of SIPl shRNA-
expressing MCF10A cells compared to control cells in the Boyden chamber assay. Data are expressed as fold 
induction for SIPl shRNA-expressing cells relative to the control cells (P<0.05). 
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Figure 5 SIP1 siRNA decreased vimentin expression in BT-549 cells. BT549 cells were transfected with either 
two different siRNA sequences against SIP1 (SIPsi1, SIPsi2) or two control siRNAs (cont1 and cont2). (a) RT-
PCR analyses of vimentin and SIP1 in the SIP1 siRNA-expressing cells compared to the control cells. 
Quantification of RT-PCR analyses of vimentin normalized for the 28S rRNA values in three independent 
transfection experiments is shown. Data are expressed as fold induction in SIP1 siRNA-expressing cells relative 
to the controls (P<0.01). (b) Western blot analyses of vimentin expression in SIP1 siRNA-expressing cells. Actin 
was used as a control. A representative experiment is shown out of three independent experiments performed. 
 
 
Figure 6 SIP1 expression inversely correlates with E-cadherin expression. RT-PCR analyses of E-cadherin in 
five breast tumor cell lines (a), in the migratory (mig) versus stationary (stat) subpopulations of VP-EGFP 
MCF10A cells plated in the migration assay (b) and in MCF10A cells transiently transfected with SIP1 cDNA 
for 24, 48 or 72h (c). Quantifications of RT-PCR analyses of E-cadherin normalized for the 28S rRNA values in 
three independent experiments are shown for (b) and (c). Data are expressed as fold induction in the migratory 
subpopulation relative to the stationary subpopulation for (b) (P<0.05) and in the SIP1 transfectants relative to 
the backbone vector transfectants for (c) (P<0.05). 
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Figure 7 No implication of the β-catenin/TCF pathway in the regulation of vimentin by SIP1. (a) Vimentin 
promoter reporter assay. The human vimentin promoter luciferase reporter plasmid was cotransfected in 
MCF10A cells either with the SIP1 cDNA expression vector (SIP1) or with the corresponding control vector 
(Cont). Data are expressed as fold induction in SIP1 transfectants relative to the values obtained in the cells 
transfected with the backbone control vector (P<0.01). (b) TOP-FLASH/FOP-FLASH reporter assay. The TOP-
FLASH or FOP-FLASH reporter plasmid was cotransfected in MCF10A cells with a control vector (Cont) or the 
SIP1 expression vector (SIP1). The normalized FOP values were subtracted from the normalized TOP values. 
Data are expressed as fold induction relative to the values obtained in the cells transfected with the control 
vector (P>0.05). Cotransfection with the β-catenin and TCF-4 expression vectors was performed as a control 
(P<0.02). (c) Western blotting analyses of β-catenin in cytosolic, nuclear and membranous fractions of MCF10A 
cells transfected either with the SIP1 expression vector (SIP1) or with the backbone control vector (Cont). The 
presence of the myc-tagged SIP1 is also shown in the nucleus of SIP1-transfected cells. Endogenous actin and  





In the present study, we demonstrate that SIP1 regulates vimentin expression in epithelial cells and emphasize 
the implication of this regulation in epithelial breast cancer cell migration/invasion. We indeed show that (1) 
SIP1 expression coincided with vimentin expression in invasive breast tumor cell lines, (2) SIPl and vimentin 
expression were specifically induced in migratory epithelial MCF10A cells, (3) SIP1 cDNA transfection 
increased vimentin expression and migratory abilities of MCF10A cells, (4) SIP1-specific siRNA or shRNA 
diminished vimentin expression in invasive breast tumor cell lines and (5) the activation of the vimentin 
promoter by SIPl was not associated with the activation of the β-catenin/TCF/LEF signaling pathway. 
Upon examination of several human breast cancer cell lines, we found a clear correlation between vimentin and 
SIPl expression in invasive cell lines. A correlation between vimentin and SIP1 expression was also obvious in 
the assay of MCF10A cell migration. Previously, this dynamic model allowed to clearly show the induction of 
vimentin during cell migration, discriminating a sub-population of migratory, vimentin-positive cells from a 
vimentin-negative, stationary subpopulation within the same cell line (Gilles et al., 1999). Here, we were able to 
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demonstrate increased SIPl expression specifically in the vimentin-positive migratory subpopulation. In 
agreement with previous studies (Sommers et al., 1994; Comijn et al., 2001; Gilles et al., 2003), a lower level of 
E-cadherin was observed both in the invasive cell lines, as well as in the migratory subpopulation of MCF10A, 
also attesting the EMT-derived phenotype of these invasive and migratory cells expressing SIP1. In line with our 
observations, SIP1 expression has been associated with migratory and invasive mechanisms occurring during 
embryonic development. Indeed, a high level of SIP1 has been detected during the formation of the neural tube 
and this has been shown to play a key role in the migration of neural crest cells (Eisaki et al., 2000; van 
Grunsven et al., 2000; Van de Putte et al., 2003), a system largely described as a physiological archetypal model 
of EMT (Duband et al., 1995; Tucker, 2004). Also, an increased expression of SIP1 has been described in 
NMuMG cells which have undergone a TGFβ1-induced EMT characterized by decreased E-cadherin expression 
and increased N-cadherin expression (Maeda et al., 2005). Our results thus demonstrate a relationship between 
SIP1 and an EMT-derived phenotype characterized by vimentin expression, and further emphasize the 
implication of this relationship in dynamic cell migration. 
We further observed that transfection of SIP1 cDNA in MCF10A cells increased vimentin expression both at the 
mRNA and protein level, which was associated with increased migratory ability. Inversely, the expression of 
SIP1-specific shRNAs in MCF10A cells clearly diminished vimentin expression as well as their migratory 
properties. Strengthening these data, a diminution of vimentin expression following SIP1 siRNA transfection 
was also shown in BT549 breast tumor cells. Up to now, the implication of SIP1 in EMT phenomena associated 
with tumor cell invasion has been more particularly linked to its ability to repress E-cadherin, as shown in 
MDCK cells and in hepatocellular and colon epidermoid carcinoma cells transfected with SIP1 (Comijn et al., 
2001; Miyoshi et al., 2004; Vandewalle et al., 2005). A repression of E-cadherin by SIP1 was accordingly 
observed in our cell systems. Overall, an increasing number of zinc-finger transcription factors, including Snail 
and Slug, both belonging to the Snail family, have been described as E-cadherin repressors and have been 
implicated in the regulation of EMT phenomena (Nieto, 2002; Come et al., 2004). Forcing the expression of 
these factors in a variety of epithelial cell systems was found to induce EMT processes characterized by 
decreased E-cadherin levels and by increased migratory/invasive properties (Cano et al., 2000; Hajra et al., 
2002; Nieto, 2002; Come et al., 2004; Peinado et al., 2004). Accumulating data now also show that these factors 
can modulate the expression of other genes implicated in tumor cell invasion. For instance, they have been 
shown to downregulate other cell-cell contact molecules but also to upregulate 'mesenchymal' genes including 
fibronectin, vimentin and members of the matrix metalloproteases (MMP) family (Savagner et al., 1997; Cano et 
al., 2000; Hajra et al., 2002; Bolos et al., 2003; Ikenouchi et al., 2003; Yokoyama et al., 2003; Ohkubo and 
Ozawa, 2004; Vandewalle et al., 2005). Much less is known regarding the δEF1/ZEB family. Recent studies 
have nevertheless shown that SIP1-induced EMT in hepatocellular and in colon epidermoid carcinoma cells is 
also associated with an increased expression of N-cadherin and mesenchymal p120ctn isoforms (Vandewalle et 
al., 2005) as well as several members of the MMP family (Miyoshi et al., 2004). Thus, together with our 
observations that expression of endogenous vimentin and SIP1 associates with migratory/invasive abilities, these 
results suggest that SIP1 can contribute to the upregulation of vimentin transcription such as that occurs during 
epithelial cell migration/invasion. 
The mechanism by which SIP1 regulates vimentin remains unclear. SIP1 has been described as a transcriptional 
repressor downregulating target genes through direct binding of bipartite elements made of one 5'-CACCT-3' 
and one 5'-CACCTG-3' sequence (Remacle et al., 1999). The fact that vimentin is upregulated by SIP1 and that 
no such bipartite element could be found in the vimentin promoter sequence suggested that vimentin regulation 
by SIP1 is most likely indirect. Considering the repressive effect of SIP1 effect on E-cadherin (Comijn et al., 
2001; van Grunsven et al., 2003), it was tempting to speculate that SIP1 induction of vimentin could depend on 
the activation of the β-catenin/TCF pathway. Although it is not always observed (Comijn et al., 2001), 
diminished E-cadherin expression could indeed favor translocation of β-catenin in the nucleus where it can 
trigger the transcription of several target genes through binding with members of the TCF/LEF transcription 
factor family (Hecht and Kemler, 2000; Giles et al., 2003). Furthermore, vimentin has been shown to be a target 
of the β-catenin/TCF pathway (Gilles et al., 2003). However, our present results rather suggest that the                   
β-catenin/TCF pathway is not activated following SIP1 transfection, as also observed by Comijn et al. (2001) in 
MDCK cells. Indeed, transfection of SIP1 cDNA into MCF10A cells did not lead to an increase in the TOP-
FLASH reporter system though it activated the vimentin promoter. Also, in agreement with our TOP-FLASH 
results, we did not observe any accumulation of nuclear β-catenin in SIP1-transfected MCF10A cells. It has also 
to be noticed that SIP1 downregulation by siRNA in invasive BT549 cells, which do not express E-cadherin, can 
also modulate vimentin expression. Taken together, these data therefore suggest that regulation of vimentin by 
SIP1 can be independent of E-cadherin expression and does not necessarily rely in modulations of the                     
β-catenin/TCF pathway. Nevertheless, many other indirect mechanisms could be involved. Additionally, the 
possibility that SIP1 could directly bind to and activate the vimentin promoter (through the binding of a single 
CACCT motif or another motif similar in sequence) cannot be excluded and is currently under investigation. 
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In conclusion, our results clearly demonstrate that SIP1 and vimentin expression correlate with a 
migratory/invasive phenotype and that SIP1 can regulate vimentin expression in epithelial breast tumor cells. 
Because of the established functional role of vimentin in cell migration, the upregulation of vimentin by SIP1 
has implications for all processes requiring epithelial cell migration including tumor cell invasion. 
Materials and methods 
Cell culture 
All human mammary epithelial cells used were obtained from the American Type Culture Collection (Rockville, 
MD, USA). MCF10A-VP-EGFP cells were generated previously by stable transfection of MCF10A cells with 
the VP-EGFP plasmid in which the human vimentin promoter controls the expression of EGFP (Gilles et al., 
1999). MCF-7, T47D, MDA-MB-231, BT549 and Hs578T cells were cultured in Dulbecco's modified Eagle's 
medium (DMEM) containing 10% FCS. MCF10A cells were grown in a 1:3 (v/v) mixture of HAM F12 and 
DMEM, supplemented with 20 µg/ml of adenine, 5 µg/ml of insulin, 0.5 µg/ml of hydrocortisone, 2 ng/ml of 
EGF, 5 µg/ml of transferrin, 1.5 ng/ml of triiodothyronin and 10% FCS. 
Primary epithelial cells and primary fibroblasts were isolated from human polyps as previously described 
(Million et al., 2001). Primary epithelial cells were allowed to differentiate, as attested by the presence of ciliated 
cells, in a transwell chamber coated with collagen type I for 12 days (Million et al., 2001). 
In vitro migration assay 
In order to sort by FACS the vimentin-expressing migratory cells from the stationary, vimentin-negative cells, 
we used two clones of MCF10A-VP-EGFP expressing the EGFP reporter gene driven by the vimentin promoter 
(MCF10A-VP-EGFP #11 and #12 as also described in Gilles et al., 1999). These cells were analysed in a 
migration assay as described previously (Gilles et al., 1999). Briefly, 5 × 104 cells were seeded in growth 
medium inside a 6-mm glass ring. At 24h after plating, the glass ring was removed and the cells were covered 
either with complete growth medium (containing FCS and EGF) or with FCS-free growth medium in order to 
examine the implication of EGF. In this model, the cells migrate as an outgrowth from the confluent area 
initially delimited by the ring. We have previously shown that cells at the periphery of the outgrowth are 
implicated in an oriented migration and express vimentin and GFP. In contrast, the cells in the area initially 
delimited by the ring are rather stationary and do not express vimentin nor GFP (Gilles et al., 1999). At 48h after 
the removal of the ring, the cells were collected by trypsinization of 24 migration assays and were sorted by 
FACS (FACSVantage-SE, Becton Dickinson, Erembodegem, Belgium) into EGFP-positive and EGFP-negative 
populations, which were then used for RNA extraction and RT-PCR analysis. 
Immunofluorescence 
Cells cultured in the migration assay on glass coverslips were fixed in paraformaldehyde (4% in PBS) for 10 min 
and then permeabilized with 0.1% Triton X-100 for 1 min at room temperature. The coverslips were then 
blocked for 30 min with 3% BSA in PBS. After several washes with PBS, fixed monolayers were incubated for 
1h with a monoclonal antibody to vimentin (clone V9, Dako, Glostrup, Denmark) and then exposed to a TRITC-
conjugated rabbit anti-mouse antibody (Dako). Finally, nuclei were labeled with 4',6-diamidino-2-phenylindole 
(DAPI; 1 µg/ml) for 20 min. The coverslips were then mounted with Aquapolymount antifading solution (Agar, 
UK) onto glass slides and observed under a fluorescence microscope (Olympus, Tokyo, Japan). 
Plasmids 
The vimentin promoter luciferase reporter vector (VimPro) used in this study has been characterized previously 
(Gilles et al., 2003). This plasmid consists of the human vimentin promoter cloned into the firefly luciferase 
reporter plasmid pGL-3 (Promega, Madison, WI, USA). 
The expression vector for the SIP1 cDNA encoding a myc-tagged protein has been described previously 
(Verschueren et al., 1999; Comijn et al., 2001). 
An expression vector encoding a mutated form of β-catenin which is less susceptible to degradation was kindly 
provided by Dr K Orford and Dr S Byers (Lombardi Cancer Center, Georgetown University, Washington, DC, 
USA) (Orford et al., 1997). Dr HC Clevers (University Hospital, Utrecht, The Netherlands) donated the 
expression vector encoding human TCF-4 (pCDNA-hTCF4) and the TOP-FLASH and FOP-FLASH plasmids 
containing, respectively, three wild-type (5'-CCTTTGATC-3': TOP-FLASH) or mutated (5'-CCTTTGGCC-3': 
FOP-FLASH) copies of the β-catenin/ TCF-binding sites upstream of a minimal c-fos promoter driving the 
expression of firefly luciferase (Korinek et al., 1997; van de Wetering et al., 1997). 
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Luciferase reporter assay 
Transient transfections were performed with Fugene transfection reagent (Roche, Branchburg, NJ, USA) on 
50000 cells plated in a 24-well plate half an hour before the addition of the DNA/Fugene mixture. 
For the determination of the vimentin promoter induction by SIP1, each well was supplemented with a mixture 
containing 20 µl of serum-free DMEM, 0.6 µl of Fugene and 0.2 µg of the promoter reporter construct (either 
VimPro, TOP-FLASH or FOP-FLASH reporter construct), 0.2 µg of the SIP1 expression vector (or the 
backbone vector control) and 1.6 ng of the Renilla luciferase reporter phRG-TK (Promega) used as an internal 
control. For β-catenin/TCF-4 induction, each well was incubated with a mixture containing 20 µl of serum-free 
DMEM, 0.6 µl of Fugene, 0.15 µg of the firefly luciferase reporter plasmid (either VimPro, TOP-FLASH or 
FOP-FLASH reporter construct), 0.15 µg of the β-catenin expression vector (or the corresponding backbone 
vector), 0.15 µg of the TCF-4 expression vector (or the corresponding backbone vector) and 1.6 ng of the Renilla 
luciferase vector phRG-TK. 
At 24h after transfection, the cells were lysed in 100 µl of lysis buffer followed by determination of luciferase 
activity in 20 µl of lysate with a luminometer using the Dual Luciferase Assay System (Promega). The firefly 
luciferase activity was normalized to the activity of the Renilla luciferase used as internal control. Results were 
expressed as fold induction, calculated by dividing the normalized values obtained following cDNA transfection 
by the normalized values obtained following transfection of the corresponding backbone expression vector. To 
assess the β-catenin/TCF/LEF activities using the TOP/FOP-FLASH reporter system, the normalized values 
obtained with the FOP-FLASH reporter plasmid were subtracted from the normalized values obtained with the 
TOP-FLASH reporter plasmid. Results were then expressed as fold induction relative to the value obtained in the 
cells transfected with the control vector. Each experiment was performed at least three times in triplicate. Data 
are expressed as means ± s.e. A one-sample t-test was performed and a P-value <0.05 was considered 
significant. 
Transient transfections of Smad interacting protein-1 cDNA  
To study the regulation of the endogenous vimentin gene by SIP1, 150000 MCF10A cells plated in six-well 
plates were transiently transfected with the SIP1 expression vector using Lipofectamine 2000 transfection 
reagent (Invitrogen, Carlsbad, CA, USA). At 24h after plating, transfection was carried out as recommended by 
the manufacturer by adding, in each well, a mixture containing 500 µl of serum-free medium, 3 µl of 
Lipofectamine 2000 and 2 µg of the SIP1 expression vector. As control, cells were transfected with the 
corresponding backbone vector. At 24, 48 and 72h after transfection, cells were collected for RT-PCR or 
Western blotting analyses. A control transfection condition using a plasmid encoding GFP (pEGFP-IRESpuro, 
Clontech, CA, USA) was always performed in parallel to determine the transfection efficiency. All experiments 
were set up to obtain at least 70% of transfected cells. 
Transfection of small interfering RNA 
Two 19-nt-specific sequences were selected in the coding sequence of SIP1 to generate 21-nt sense and 21-nt 
antisense strands of the type (19N) TT (N, any nucleotide). The sense and antisense strands were then annealed 
to obtain duplexes with identical 3' overhangs. The sequences were submitted to a BLAST search against the 
human genome to ensure the specificity of the small interfering RNA (siRNA) to the targeted sequence. Two 
duplexes, which do not recognize any sequence in the human genome, were used as controls. The 19-nt-specific 
sequences for the two SIP1 siRNAs are as follows: SIP1 Si1, 5'-GGUAAUCGCAAGUUCAAAU-3'; SIP1 Si2, 
5'-GAACAGACAGGCUUACUUA-3'. For transfection of the siRNA duplexes, 75 000 cells were plated in six-
well plates in 2 ml/well of culture medium. At 24h after plating, the cells were transfected by phosphate calcium 
precipitation by adding in each well 200 µl of a mixture containing the siRNA duplexes (20 nM), 140 mM NaCl, 
0.75 mM Na2H-PO4, 6 mM glucose, 5 mM KCl, 25 mM HEPES and 125 mM CaCl2. At 24h after transfection, 
the cells were extensively washed with PBS and incubated for 48h in culture medium before they were harvested 
for RT-PCR analyses or Western blotting analyses. The transfection of an FITC-labelled control siRNA 
(Eurogentec, Belgium) was also performed in parallel and revealed an uptake of the siRNA in 100% of the cells. 
Transduction of the lentiviral vector for SIP1 short hairpin RNA  
A SIP1-specific siRNA sequence was designed using selection criteria as described (Brummelkamp et al., 2002; 
Ui-Tei et al., 2004). A double PCR approach was used to create shRNA expression cassettes containing the H1 
promoter and both the sense and antisense shRNA sequences with a loop sequence in between. In a first step, 
PCR was performed using pSuper plasmid (Brummelkamp et al., 2002) as a template, the H1 promoter primer 
5'-CTGCAGGAATTCGAACGCTGACGT CATCAA-3' and the sense shRNA oligonucleotide 5-AAATC 
TCTTGAATTTAACAATACCCAGCTCCGGGGATCTGT GGTCTCATACAGAACTTATAA-3' (SEC1 = 
SIP1shl) or 5'-TGTTCTCTTGAAACAAAGGTAACGTTCATGCGGG 
GATCTGTGGTCTCATACAGAACTTATAA-3' (SEC8 = SIP1sh2). This PCR product was a template for a 
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second PCR reaction with the same H1 promoter primer and the antisense shRNA oligonucleotide                            
5'-CCATCGATAAGCTTT TTTTCCAAAAAAGGAGCTGGGTATTGTTAAATCTCT TGAATTTA-3' (SEC1 
= SIP1sh1) or 5'-CCATCGATAAGC TTTTTTTCCAAAAAAGCATGAACGTTACCTTTGTTC 
TCTTGAAACAA-3' (SEC8 = SIP1sh2). The shRNA expression cassette was cloned in the lentiviral pLV-TH 
vector (Wiznerowicz and Trono, 2003) using EcoRI and ClaI restriction sites. 
For lentivirus production, 1.2 million cells of the packaging cell line HEK293T were seeded in a 25-cm2 flask. 
After 24h, 3 µg of the pLV-THshRNA construct or empty vector, 3 µg of the packaging plasmid pCMVdR8.91 
and 1.5 µg of the envelope plasmid pMD2G-VSVG were first precipitated together and then transfected into the 
HEK293T cells using the calcium phosphate precipitation method. The DNA was premixed with 50 µl of 2 M 
CaCl2 and 190 µl TE buffer and then slowly added to 250 µl 2 × HBS. The mixture was put on a shaker for 15 
min before it was added to the cells. After 8h, the cells were washed and incubated for 48h in 4 ml fresh culture 
medium. The virus-containing medium was then harvested and filtered through a 0.45 µm low protein binding 
filter unit (Millipore, Billerica, MA, USA). Aliquots were stored at -70°C. 
Transduction of the MCF10A cells was performed by mixing 50000 cells with 200 µl viral supernatant in a 96-
well plate and three replicates of each transduction were made. These mixtures were centrifuged for 1.5h at 32°C 
and 1500 r.p.m. before putting them in the 37°C incubator. After 24 h, the cells were trypsinized and replicates 
were pooled in a 24-well plate together with 800 µl fresh viral supernatant. The mixtures were again centrifuged 
as mentioned above and incubated for 24h before replacing the medium with fresh culture medium. 
Transduction efficiencies were determined by measuring EGFP expression using FACS analysis (Epics Altra 
from Beckman Coulter, Fullerton, CA, USA). Subsequently, the cells were sorted to obtain cell populations with 
more than 90% EGFP-positive cells. 
Western blotting analyses 
Total protein extracts were prepared in RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% (v/v) Igepal, 1% 
(w/v) sodium deoxycholate, 5 mM iodoacetamide, 0.1% (w/v) SDS), containing complete protease inhibitor 
cocktail (Roche). To examine the subcellular distribution of β-catenin, cytosolic, membranous and nuclear 
extracts of MCF10A cells transfected with the SIP1 expression vector (or the corresponding backbone vector) 
for 48h were prepared using the ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem, LaJolla, CA, 
USA). Protein concentration was determined with the DC protein assay (BioRad, Richmond, CA, USA). In all, 
10 µg or 500 ng of total protein were separated on 15% SDS-PAGE gels for analysis of vimentin in MCF10A 
and BT549 cells, respectively. Total protein extract of MCF10A cells (500 ng) was separated on 10% SDS-
PAGE gels for E-cadherin analysis. In total, 4 µg of cytosolic or nuclear extracts and 1 µg of membranous 
extracts of MCF10A cells were separated on 10% SDS-PAGE to analyse the expression of β-catenin. Proteins 
were transferred to PVDF membranes (NEN, Boston, MA, USA), which were then blocked with 5% milk (w/v) 
+ 0.1% Tween 20 (w/v) in PBS for 2h. They were then exposed to primary antibodies overnight at 4°C: a 
monoclonal antibody (mAb) to vimentin (clone V9, Dako), an mAb to E-cadherin (BD Transduction 
Laboratories, San Jose, CA) or an mAb to β-catenin (either from BD Transduction Laboratories or clone 8E4 
from AG Scientific, CA, USA, which is a specific antibody for the unphosphorylated form of β-catenin). The 
filters were then incubated with a horseradish peroxidase-conjugated swine anti-mouse antibody (Dako). Signals 
were detected with an enhanced chemiluminescence (ECL + ) kit (Amersham Pharmacia Biotech, 
Buckinghamshire, UK). Subsequent detection of actin (using a rabbit antibody to actin, clone A2066, Sigma-
Aldrich, St Louis, MO, USA), or c-myc (using an mAb to c-myc, clone 9E10, Sigma) was performed on the 
same filters as a control. Western blotting analyses were performed on three independent experiments and a 
representative experiment is shown in the figures. 
RT-PCR analysis 
Total RNA was extracted with an RNA isolation kit (Roche). RT-PCR was performed using 10 ng of total RNA 
and the GeneAmp Thermostable RNA PCR Kit (Perkin Elmer, Foster City, CA, USA). Forward and reverse 
primers (Eurogentec, Seraing, Belgium) were as follows: vimentin primers (forward 5'-
GACAATGCGTCTCTGGCACGTCTT-3', reverse 5'-TCCTCCGCCTCCTGCAGGTTCTT-3'), SIP1 primers 
(forward 5'-AGTCCATGCGAACTGCCATCTGAT-3', reverse 5'- CTGGACCATCTACAGAGGCTTGTA-3'), 
E-cadherin primers: (forward 5'-CCCATCAGCTGCCCAGAAAATGA A-3', reverse 5'- 
CTGTCACCTTCAGCCATCCTGTTT-3'), 28S rRNA primers (forward 5'-GTTCACCCACTAATAGGG 
AACGTGA-3', reverse 5'-GGATTCTGACTTAGAGGCGT TCAGT-3'). Reverse transcription was performed at 
70°C for 15 min. Products were separated on acrylamide gels, stained with SYBR Gold (Molecular Probes, 
Eugene, OR, USA) and quantified by fiuorimetric scanning (LAS-1000, Fuji, Stamford, CT, USA). 
Quantification was performed by normalization of the values obtained for 28 S rRNA amplification. For SIP1 
cDNA transfection or RNAi experiments, results were expressed as fold induction calculated by dividing the 
normalized value of a given condition (SIP1 cDNA transfection, SIP1 siRNA transfection or SIP1 shRNA 
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transduction) by the normalized value of the corresponding control. Each experiment was performed at least 
three times.  Data are expressed as means ± s.e. A one-sample t-test was performed and a P-value <0.05 was 
considered significant. 
Boyden chamber invasion assay 
The migratory properties of MCF10A cells transfected with SIP1 cDNA for 48h or transduced with the 
SIP1shRNA lentiviral vector were assessed using the Boyden chamber assay. Cells (100000) were suspended in 
300 µl of serum-free medium supplemented with 0.1% BSA and placed in the upper compartment of a 24-well 
transwell (Costar, NY, USA). The lower compartment was filled with 600 µl of medium containing 10% FCS 
and 1% BSA. After 6h of incubation at 37°C, the filters were fixed in methanol for 10 min and stained with 
Giemsa for 30 min. Cells on the upper surface of the filters were wiped away with a cotton swab. Migration was 
quantified by counting the number of cells on the lower surface of the filters. Experiments were performed at 
least three times in triplicate. Data are expressed as means ± s.e. A one-sample t-test was performed and a P-
value <0.05 was considered significant. 
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